TrialJournal of cancer research and clinical oncology2019

A randomized phase II, open-label and multicenter study of combination regimens of bortezomib at two doses by subcutaneous injection for newly diagnosed multiple myeloma patients.

Feng Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.